Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain

References

• Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–815.
   PubMed Web of Science ®Google Scholar
• Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650.
   PubMed Web of Science ®Google Scholar
• Guo JD, Hlavacek P, Poretta T, et al. Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. J Thromb Thrombolysis. 2020;50(2):386–394.
   PubMed Web of Science ®Google Scholar
• Soff GA, Mones J, Wilkins C, et al. Rivaroxaban treatment of cancer‐associated venous thromboembolism: memorial sloan kettering cancer center institutional experience. Res Pract Thromb Haemost. 2019;3(3):349–356.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost. 2018;118(9):1668–1678.
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–291.
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of Cancer-Associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850.
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE Investigators;Büller HR,Décousus H,Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New Eng J Med. 2013;369(15):1406–1415.
   PubMed Web of Science ®Google Scholar
• Kimpton M, Carrier M. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opin Drug Saf. 2019;18(4):313–320.
   PubMed Web of Science ®Google Scholar
• Guo W-Q, Chen X-H, Tian X-Y, et al. Differences in gastrointestinal safety profiles among novel oral anticoagulants: evidence from a network meta-analysis. Clin Epidemiol. 2019;11:911–921.
   PubMed Web of Science ®Google Scholar
• Li A, Manohar PM, Garcia DA, et al. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019;180:37–42.
   PubMed Web of Science ®Google Scholar
• Giustozzi M, Agnelli G, del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120(7):1128–1136.
   PubMed Web of Science ®Google Scholar
• Marin-Barrera L, Muñoz-Martin AJ, Rios-Herranz E, et al. A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: quality of life in cancer (QCA) study. Cancers. 2019;12(1):75.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974.
   PubMed Web of Science ®Google Scholar
• Noble S, Matzdorff A, Maraveyas A, et al. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015;100(11):1486–1492.
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Dewilde S, Noble S, et al. What impact does venous thromboembolism and bleeding have on cancer patients' quality of life? Value Health. 2018;21(4):449–455.
   PubMed Web of Science ®Google Scholar
• Li A, Carlson JJ, Kuderer NM, Schaefer JK, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020;126(8):1736–1748.
   PubMed Web of Science ®Google Scholar
• Streiff MB, Abutalib SA, Farge D, et al. Update on guidelines for the management of cancer‐associated thrombosis. Oncologist. 2021;26(1):e24–e40.
   PubMed Web of Science ®Google Scholar
• McBane RD, Wysokinski WE, Le‐Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607.
   PubMed Web of Science ®Google Scholar
• Rubio Salvador A, Perez Segura P. Coste por paciente con heparina de bajo peso molecular en el tratamiento extendido de tromboembolismo venoso y la prevención de recurrencias en pacientes con cáncer activo. Albacete: XXXIX Jornada de la Asociación Economia de la Salud 2019.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Ende-Verhaar Y, Cannegieter S, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017;49(2):1601792.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Shapiro S, Wells PS, Rodger MA, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014;383(9920):880–888.
   PubMed Web of Science ®Google Scholar
• Spanish National Statistics Institute (INE). Mortality Tables by year, sex, age and functions. National results by region and province. Spain, INE; 2018.
   Google Scholar
• Tramontano AC, Schrag DL, Malin JK, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states. Med Decis Making. 2015;35(3):371–387.
   PubMed Web of Science ®Google Scholar
• Hogg K, Kimpton M, Carrier M, et al. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173(12):1067.
   PubMed Web of Science ®Google Scholar
• Locadia M, Bossuyt P, Stalmeier P, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost. 2004;92(6):1336–1341.
   PubMed Web of Science ®Google Scholar
• Preblick R, Kwong WJ, White RH, et al. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. Hosp Pract. 2015;43(5):249–257.
   PubMedGoogle Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4(1):49–56.
   PubMed Web of Science ®Google Scholar
• Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–329.
   PubMed Web of Science ®Google Scholar
• General Council of Pharmaceutical Associations. Drug Cost Database. BotPlus. Spain GCPA; 2020.
   Google Scholar
• Healthcare SM. Real Decreto-Ley 8/2010; 2020.
   Google Scholar
• Ministry SH. Registro de Atención Especializada (RAE-CMBD). Desde 2016 en adelante; 2021. Available from: https://pestadistico.inteligenciadegestion.mscbs.e
   Google Scholar
• Mukdad MA, Al-Badriyeh D, Elewa HF. Cost-effectiveness evaluations among the direct oral anticoagulants for the prevention and treatment of venous thromboembolism: systematic review. Clin Appl Thromb Hemost. 2019; 25:107602961984910.
   Web of Science ®Google Scholar
• Given BA, Given CW, Vachon E, et al. Do we have a clue: the treatment burden for the patient with cancer? Cancer Nurs. 2016;39(5):423–424.
   PubMed Web of Science ®Google Scholar
• Van Der Wall SJ, Klok FA, Den Exter PL, et al. Higher adherence to treatment with low-molecular-weight-heparin nadroparin than enoxaparin because of side effects in cancer-associated venous thromboembolism. Hemasphere. 2018;2(1):e19.
   PubMed Web of Science ®Google Scholar
• Connell NT, Connors JM. Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. J Thromb Thrombolysis. 2019;48(3):382–386.
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Stewart KD, et al. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res. 2017;17(1):774.
   PubMed Web of Science ®Google Scholar
• Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153.
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735.
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–396.
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072.
   PubMed Web of Science ®Google Scholar
• Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686.
   PubMed Web of Science ®Google Scholar